NCT02750761View on ClinicalTrials.gov

A Study of Oral and Intravenous (IV) Tedizolid Phosphate in Hospitalized Participants, Ages 2 to <12 Years, With Confirmed or Suspected Bacterial Infection (MK-1986-013)

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

May 2, 2016

Primary Completion Date

December 16, 2018

Study Completion Date

December 21, 2018

Conditions
Gram-Positive Bacterial Infections
Interventions
DRUG

Tedizolid Phosphate (IV)

200 mg/vial powder for injection

DRUG

Tedizolid Phosphate (oral suspension)

Powder for oral suspension 20 mg/mL following reconstitution

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02750761 - A Study of Oral and Intravenous (IV) Tedizolid Phosphate in Hospitalized Participants, Ages 2 to <12 Years, With Confirmed or Suspected Bacterial Infection (MK-1986-013) | Biotech Hunter | Biotech Hunter